The SPRINT trial, published Nov 9 in the New England Journal of Medicine, is the biggest news in blood pressure treatment in many years. (1) It will definitely change how we treat blood pressure.
The trial studied persons with a systolic blood pressure of greater than 130 mm Hg and increased cardiovascular risk. The SPRINT study clearly demonstrated that these patients experienced marked benefit from having their blood pressure lowered to a systolic blood pressure of less 120 mm Hg. (2)
The trial was stopped early, after a median
follow-up of 3.26 years. Overall, participants assigned
to the intensive-treatment group, as compared
with those assigned to the standardtreatment
group, had a 25% lower relative risk of
major cardiovascular events (95% confidence
interval [CI], 11 to 36), with consistent results
across subgroups defined according to age, sex,
race, medical history, and baseline blood pressure.
In addition, the intensive-treatment group
had a 27% lower relative risk of death from any
cause (95% CI, 10 to 40).
(3) Supplementary Appendix [Full Text PDF]
This appendix has been provided by the authors to give readers additional information about their work. Supplement to: The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. DOI: 10.1056/NEJMoa1511939